Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP343257.RASKJiXlCLoAg45DKkrpkvb-Ed_1j4coTQhkP_7_KEKbY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP343257.RASKJiXlCLoAg45DKkrpkvb-Ed_1j4coTQhkP_7_KEKbY130_assertion type Assertion NP343257.RASKJiXlCLoAg45DKkrpkvb-Ed_1j4coTQhkP_7_KEKbY130_head.
- NP343257.RASKJiXlCLoAg45DKkrpkvb-Ed_1j4coTQhkP_7_KEKbY130_assertion description "[Mutations of SLC2A2 were detected in historical FBS patients in whom some of the characteristic clinical features (hepatorenal glycogen accumulation, glucose and galactose intolerance, fasting hypoglycemia, a characteristic tubular nephropathy) and the effect of therapy were described for the first time.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP343257.RASKJiXlCLoAg45DKkrpkvb-Ed_1j4coTQhkP_7_KEKbY130_provenance.
- NP343257.RASKJiXlCLoAg45DKkrpkvb-Ed_1j4coTQhkP_7_KEKbY130_assertion evidence source_evidence_literature NP343257.RASKJiXlCLoAg45DKkrpkvb-Ed_1j4coTQhkP_7_KEKbY130_provenance.
- NP343257.RASKJiXlCLoAg45DKkrpkvb-Ed_1j4coTQhkP_7_KEKbY130_assertion SIO_000772 11810292 NP343257.RASKJiXlCLoAg45DKkrpkvb-Ed_1j4coTQhkP_7_KEKbY130_provenance.
- NP343257.RASKJiXlCLoAg45DKkrpkvb-Ed_1j4coTQhkP_7_KEKbY130_assertion wasDerivedFrom befree-2016 NP343257.RASKJiXlCLoAg45DKkrpkvb-Ed_1j4coTQhkP_7_KEKbY130_provenance.
- NP343257.RASKJiXlCLoAg45DKkrpkvb-Ed_1j4coTQhkP_7_KEKbY130_assertion wasGeneratedBy ECO_0000203 NP343257.RASKJiXlCLoAg45DKkrpkvb-Ed_1j4coTQhkP_7_KEKbY130_provenance.